Jinhe Biotechnology Co Ltd (002688) - Total Assets
Based on the latest financial reports, Jinhe Biotechnology Co Ltd (002688) holds total assets worth CN¥5.58 Billion CNY (≈ $817.26 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 002688 net assets for net asset value and shareholders' equity analysis.
Jinhe Biotechnology Co Ltd - Total Assets Trend (2008–2024)
This chart illustrates how Jinhe Biotechnology Co Ltd's total assets have evolved over time, based on quarterly financial data.
Jinhe Biotechnology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jinhe Biotechnology Co Ltd's total assets of CN¥5.58 Billion consist of 35.8% current assets and 64.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.3% |
| Accounts Receivable | CN¥672.91 Million | 11.9% |
| Inventory | CN¥635.28 Million | 11.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥715.26 Million | 12.7% |
| Goodwill | CN¥460.30 Million | 8.2% |
Asset Composition Trend (2008–2024)
This chart illustrates how Jinhe Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 002688 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jinhe Biotechnology Co Ltd's current assets represent 35.8% of total assets in 2024, a decrease from 44.1% in 2008.
- Cash Position: Cash and equivalents constituted 11.3% of total assets in 2024, down from 12.7% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 2.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 12.7% of total assets.
Jinhe Biotechnology Co Ltd Competitors by Total Assets
Key competitors of Jinhe Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Jinhe Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.94 | 1.19 | 0.90 |
| Quick Ratio | 0.61 | 0.86 | 0.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-122.22 Million | CN¥357.61 Million | CN¥-132.91 Million |
Jinhe Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jinhe Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.01 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 3.6% |
| Total Assets | CN¥5.65 Billion |
| Market Capitalization | $679.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jinhe Biotechnology Co Ltd's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jinhe Biotechnology Co Ltd's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jinhe Biotechnology Co Ltd (2008–2024)
The table below shows the annual total assets of Jinhe Biotechnology Co Ltd from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.65 Billion ≈ $826.86 Million |
+3.61% |
| 2023-12-31 | CN¥5.45 Billion ≈ $798.06 Million |
+21.05% |
| 2022-12-31 | CN¥4.51 Billion ≈ $659.31 Million |
+10.85% |
| 2021-12-31 | CN¥4.06 Billion ≈ $594.77 Million |
+20.36% |
| 2020-12-31 | CN¥3.38 Billion ≈ $494.14 Million |
+0.97% |
| 2019-12-31 | CN¥3.34 Billion ≈ $489.37 Million |
+0.27% |
| 2018-12-31 | CN¥3.34 Billion ≈ $488.07 Million |
+12.68% |
| 2017-12-31 | CN¥2.96 Billion ≈ $433.13 Million |
+11.18% |
| 2016-12-31 | CN¥2.66 Billion ≈ $389.58 Million |
+41.22% |
| 2015-12-31 | CN¥1.89 Billion ≈ $275.86 Million |
+24.14% |
| 2014-12-31 | CN¥1.52 Billion ≈ $222.22 Million |
+49.34% |
| 2013-12-31 | CN¥1.02 Billion ≈ $148.80 Million |
+1.35% |
| 2012-12-31 | CN¥1.00 Billion ≈ $146.82 Million |
+49.57% |
| 2011-12-31 | CN¥670.84 Million ≈ $98.16 Million |
+7.52% |
| 2010-12-31 | CN¥623.92 Million ≈ $91.30 Million |
+0.86% |
| 2009-12-31 | CN¥618.59 Million ≈ $90.52 Million |
+9.20% |
| 2008-12-31 | CN¥566.45 Million ≈ $82.89 Million |
-- |
About Jinhe Biotechnology Co Ltd
Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China and internationally. It offers chlortetracycline premixes; veterinary drug and powder series; disinfectants; and sprinklers. It also engages in the production and sales of feed and raw materials. The company was founded in 1990 and is headquartered in Hohhot, China.